Anti Myelin-Associated-Glycoprotein Antibody Peripheral Neuropathy Response to Combination Chemoimmunotherapy With Bendamustine/Rituximab in a Patient With Biclonal IgM κ and IgM λ: Case Report and Review of the Literature
- 1 July 2016
- journal article
- case report
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 16 (7) , e101-e108
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Diagnosis and treatment of chronic acquired demyelinating polyneuropathiesNature Reviews Neurology, 2014
- Placebo-controlled trial of rituximab in IgM anti-myelin–associated glycoprotein neuropathyNeurology, 2013
- Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study GroupJournal of Clinical Oncology, 2012
- Rituximab induces sustained reduction of pathogenic B cells in patients with peripheral nervous system autoimmunityJournal of Clinical Investigation, 2012
- Placebo‐controlled trial of rituximab in IgM anti–myelin‐associated glycoprotein antibody demyelinating neuropathyAnnals of Neurology, 2009
- Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-hodgkin lymphomaClinical Therapeutics, 2009
- Bendamustine Plus Rituximab Is Effective and Has a Favorable Toxicity Profile in the Treatment of Mantle Cell and Low-Grade Non-Hodgkin's LymphomaJournal of Clinical Oncology, 2005
- Polyneuropathy associated with IgM monoclonal gammopathyActa Neuropathologica, 1989
- Immunofluorescence study of patients with neuropathy and IgM M proteinsAnnals of Neurology, 1985
- Prevalence of monoclonal protein in peripheral neuropathyNeurology, 1981